IFFIm raises more than US$ 2 billion to support life-saving immunisation programmes in poorest countries

Restricted Access Library

The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.

Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.

The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.

The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.

Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.

The International Finance Facility for Immunisation satisfies strong demand for ethical investments and helps ensure children are vaccinated

Press Releases 

THIS DOCUMENT IS NOT AN OFFER FOR THE SALE OF SECURITIES. THIS DOCUMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY, THE UNITED STATES

Geneva, 19 May 2009 - The International Finance Facility for Immunisation (IFFIm) has raised more than US$ 2 billion dollars on the international capital markets so far to support life-saving immunisation programmes through the GAVI Alliance.

IFFIm harnesses the strength of the public and private sectors for development and we are seeing strong demand for ethical investments such as IFFIm Vaccine Bonds.

Alan Gillespie, Chairman, IFFIm Board

Strong demand

IFFIm board chairman Alan Gillespie told participants at a meeting on innovative financing in Geneva on Tuesday that there is a strong demand among individual and institutional investors for ethical investments.

"IFFIm harnesses the strength of the public and private sectors for development and we are seeing strong demand for ethical investments such as IFFIm Vaccine Bonds," Gillespie said. "This is just the beginning and we believe we can raise another US$ 2 billion. The demand is there."

IFFIm was launched in 2006 to rapidly accelerate the availability and predictability of funds for immunisation. The funds raised are used by the GAVI Alliance, a public-private partnership which aims to reduce the number of vaccine-preventable deaths and illness among children under five. GAVI provides funds to purchase and deliver vaccines and strengthen health services in more than 70 developing countries.

IFFIm is backed by the United Kingdom, France, Italy, Spain, Sweden, Norway and South Africa which have pledged to contribute US$ 5.3 billion to IFFIm over 20 years. IFFIm converts these long-term government pledges into immediately available cash by issuing bonds on the capital markets.

An attractive and ethical investment opportunity

This strong financial base enables IFFIm to have a triple-A rating from the three major rating agencies making it an attractive and ethical investment opportunity to both individual and institutional investors alike. The World Bank acts as financial adviser and Treasury Manager to IFFIm.

"The funds raised by IFFIm help GAVI reach more children with life-saving vaccines and help us make long-term commitments to developing countries," said Dr Julian Lob-Levyt, GAVI Alliance CEO. "IFFIm is a major funding source for our programmes, but we will still need an additional US$ 400 million per year in order to reach our goals by 2015."

IFFIm's initial benchmark offering in November 2006 raised US$1 billion among institutional investors globally and a second offering in March 2008 raised the equivalent of US$ 223 million from private investors in Japan. In the first five months of 2009, IFFIm has raised an additional US$ 829 million in Japan and the UK from both private and institutional investors.

The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities legislation of any state of the United States, and may not be offered or sold in the United States, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. IFFIm does not presently intend to make a public offer of securities in the United States or to register any securities under the Securities Act. The securities referred to in this document will only be offered or sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act. 

About IFFIm
International Finance Facility for Immunisation Company (IFFIm) is a multilateral development institution created to accelerate the availability of predictable, long-term funds for health and immunisation programmes through the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation) in 70 of the poorest countries around the world.

IFFIm was created as a development financing tool to help the international community achieve the Millennium Development Goals. IFFIm's financial base consists of legally binding grants payments from its sovereign sponsors (France, Italy, Norway, South Africa, Spain, Sweden and the UK), on the basis of which IFFIm's is rated AAA/Aaa/AAA (Fitch/Moody's/S&P). The World Bank is the Treasury Manager for IFFIm. IFFIm was established as a charity with the Charity Commission for England and Wales and is registered in England and Wales as a company limited by guarantee with number 5857343 and as a charity with number 1115413.

About the GAVI Alliance
The GAVI Alliance is a public-private partnership that aims to immunise children and strengthen health systems in the world's poorest countries. It brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, NGOs, the Bill & Melinda Gates Foundation and private philanthropists. GAVI provides vaccines against diphtheria, tetanus, pertussis combined with haemophilus influenzae type b and hepatitis B as so-called pentavalent (five antigens in one vaccine) as well as vaccines against measles, yellow fever, pneumococcal diseases (pneumonia and meningitis) and rotavirus (diarrhoea).

close icon

modal window here